Pharmacogenetics of Tamoxifen: Who Should Undergo<i>CYP2D6</i>Genetic Testing?
Michaela J. Higgins(Cancer Trials Ireland), Vered Stearns(Johns Hopkins University), James M. Rae(University of Michigan), Daniel F. Hayes(University of Michigan–Ann Arbor), David A. Flockhart(Indiana University – Purdue University Indianapolis)
Cited by 59
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k